Episodios

  • Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting on the Current and Future Role of Immunotherapy and Antibody-Drug Conjugates

    Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting on the Current and Future Role of Immunotherapy and Antibody-Drug Conjugates
    Jul 17 2025

    Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations.

    CME information and select publications here.

    Más Menos
    1 h y 29 m
  • For Oncology Nurses: DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer — Proceedings from the 2025 Annual ONS Congress

    For Oncology Nurses: DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer — Proceedings from the 2025 Annual ONS Congress
    Jul 8 2025

    Dr Anne Chiang, Dr Erin Schenk, and nurse practitioners Ms Elizabeth Krueger and Ms Beth Sandy discuss the role of bispecific antibodies in the management of small cell lung cancer and strategies to mitigate and manage treatment-emergent adverse events.

    NCPD information and select publications here.

    Más Menos
    1 h y 28 m
  • EGFR Mutation-Positive Non-Small Cell Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting

    EGFR Mutation-Positive Non-Small Cell Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting
    Jun 20 2025

    Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi Jänne, Dr Suresh Ramalingam, Dr Joshua Sabari and moderator Dr Helena Yu present data informing treatment decision-making for EGFR-mutated NSCLC at the 2025 ASCO annual meeting.

    CME information and select publications here.

    Más Menos
    1 h y 58 m
  • Non-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and Advances

    Non-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and Advances
    Jun 10 2025

    Dr Jessica J Lin from Massachusetts General Hospital in Boston and Dr Joel W Neal from Stanford Cancer Institute in California summarize major treatment advances over the past year and review relevant ongoing clinical trials using targeted therapies for patients with non-small cell lung cancer.

    CME information and select publications here.

    Más Menos
    58 m
  • Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit

    Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit
    May 18 2025

    Clinical investigators discuss available data guiding the management of non-small cell lung cancer with immunotherapy and other nontargeted approaches. 

    CME information and select publications here.
    Más Menos
    50 m
  • EGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology Summit

    EGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology Summit
    Apr 30 2025

    Clinical investigators discuss available data guiding the management of EGFR mutation-positive non-small cell lung cancer. 

    CME information and select publications here.
    Más Menos
    52 m
  • For Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress

    For Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress
    Apr 26 2025

    Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events.

    NCPD information and select publications here.

    Más Menos
    1 h y 33 m
  • First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor

    First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor
    Apr 10 2025

    Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer.

    CME information and select publications here.

    Más Menos
    57 m